'Pfizer was required to conduct a similar study, with results due on Dec. 31, 2022, but the FDA changed the end date at the request of Pfizer.'
“mRNA-1273 booster vaccination-associated elevation of markers of myocardial injury occurred in about one out of 35 persons (2.8%), a greater incidence than estimated in meta-analyses of hospitalized cases with myocarditis (estimated incidence 0.0035%) after the second vaccination,” the researchers wrote in the paper, published by the European Journal of Heart Failure.
In a generally healthy population, the level would be about 1 percent, the researchers said.


